newsfilter
← Latest News
GlobeNewswire·

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with